EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Vaccinome Landscape in Nearly 620 000 Patients With Diabetes

Francesca D'Addio, Elisa Lazzaroni, Maria Elena Lunati, Giuseppe Preziosi, Michele Ercolanoni, Giulio Turola, Chiara Marrocu, Giovanni Cicconi, Sudwaric Sharma, Simona Scarioni, Laura Montefusco, Ida Pastore und 16 weitere

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgae476 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Francesca D'Addio und 27 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, ASST Fatebenefratelli-Sacco, 20157 Milan, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Vaccination, Vaccination Coverage. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Italian Ministry of Health, Italian Ministry of University and Research, Italian Ministry of University Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Type 1 (T1D) and type 2 diabetes (T2D) are associated with an elevated incidence of infectious diseases and a higher risk of infections-related hospitalization and death.

Objective

In this study, we delineated the “vaccinome” landscape obtained with a large immunization schedule offered by the Regional Government of Lombardy in a cohort of 618 396 patients with diabetes (T1D and T2D).

Methods

Between September 2021 and September 2022, immunization coverage for influenza, meningococcus, pneumococcus, and herpes zoster was obtained from the public computerized registry of the health care system of Lombardy Region (Italy) in 618 396 patients with diabetes and in 9 534 087 subjects without diabetes. Type of diabetes, age, mortality, and hospitalizations were retrospectively analyzed in vaccinated and unvaccinated patients.

Results

Among patients with diabetes (T1D and T2D), 44.6% received the influenza vaccine, 10.9% the pneumococcal vaccine, 2.5% the antimeningococcus vaccine, and 0.7% the antizoster vaccine. Patients with diabetes immunized for influenza, zoster, and meningococcus showed a 2-fold overall reduction in mortality risk and a decrease in hospitalizations. A 3-fold lower risk of mortality and a decrease in hospitalizations for both cardiac and pulmonary causes were also observed after influenza, zoster, and meningococcus immunization in older patients with diabetes.

Conclusion

Immunization coverage is still far from the recommended targets in patients with diabetes. Despite this, influenza vaccination protected nearly 3800 per 100 000 patients with diabetes from risk of death. The overall impressive decrease in mortality and hospitalizations observed in vaccinated patients strengthens the need for scaling up the “vaccinome” landscape in patients with diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Diabetes Mellitus, Type 1VaccinationVaccination CoverageHumansFemaleMaleMiddle AgedAgedRetrospective StudiesHospitalizationItalyAdultInfluenza VaccinesPneumococcal VaccinesAged, 80 and overYoung AdultAdolescentMeningococcal Vaccines

Stichwörter der Autor:innen

diabeteshospitalizationimmunization coveragemortalityvaccines

Substanzen

Influenza VaccinesPneumococcal VaccinesMeningococcal Vaccines

Autor:innen und Institutionen

  • Division of Endocrinology, ASST Fatebenefratelli-Sacco, 20157 Milan, Italy.
  • International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, Department of Biomedical and Clinical Sciences, Università Degli Studi di Milano, 20157 Milan, Italy.
  • ARIA S.p.A. (The Innovation and Procurement Regional Company of Regione Lombardia), 20124 Milano, Lombardia, Italy.
  • Postgraduate School in Public Health, Department of Biomedical Sciences for Health, University of Milan, 20133 Milan, Italy.
  • IRCCS Ospedale Galeazzi-Sant'Ambrogio, Internal Medicine, 20157 Milan, Italy.
  • U.O.S. Diabetologia ASST Lariana, P.O. Mariano Comense, CO 22066, Italy.

ORCID-Profile: Paolo Fiorina

Förderung

  • Italian Ministry of Health
  • Italian Ministry of University and Research
  • Italian Ministry of University Research

Zitieren

APA

D'Addio, F., Lazzaroni, E., Lunati, M. E., Preziosi, G., Ercolanoni, M., Turola, G., Marrocu, C., Cicconi, G., Sharma, S., Scarioni, S., Montefusco, L., Pastore, I., Morpurgo, P. S., Rossi, A., Gandolfi, A., Tinari, C., Rossi, G., Ben Nasr, M., Loretelli, C., …, & Fiorina, P. (2025). Vaccinome Landscape in Nearly 620 000 Patients With Diabetes. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae476

Vancouver

D'Addio F, Lazzaroni E, Lunati ME, Preziosi G, Ercolanoni M, Turola G, et al. Vaccinome Landscape in Nearly 620 000 Patients With Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae476

BibTeX
@article{DAddio2025,
  author = {D'Addio, Francesca and Lazzaroni, Elisa and Lunati, Maria Elena and Preziosi, Giuseppe and Ercolanoni, Michele and Turola, Giulio and Marrocu, Chiara and Cicconi, Giovanni and Sharma, Sudwaric and Scarioni, Simona and Montefusco, Laura and Pastore, Ida and Morpurgo, Paola Silvia and Rossi, Antonio and Gandolfi, Alessandra and Tinari, Camilla and Rossi, Giada and Ben Nasr, Moufida and Loretelli, Cristian and Fiorina, Roberta Maria and Grassa, Baldassarre and Terranova, Rosa and Bucciarelli, Loredana and Berra, Cesare and Cereda, Danilo and Zuccotti, Gianvincenzo and Borriello, Catia Rosanna and Fiorina, Paolo},
  title = {Vaccinome Landscape in Nearly 620 000 Patients With Diabetes},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgae476}
}
Kostenlos starten →